(3SR,4aRS,6SR,8aRS)-6-(1H-Tetrazol-5-yl)decahydroisoquinoline-3-carboxylic Acid, a Novel, Competitive, Systemically Active NMDA and AMPA Receptor Antagonist

Journal of Medicinal Chemistry

Volumn 38, Issue 25, 1995, Pages 4885-4890

  Omstein, Paul L ^a   Arnold, M Brian ^a   Allen, Nancy K ^a   Leander, J David ^a   Tizzano, Joseph P ^a   Lodge, David ^a   Schoepp, Darryle D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DECAHYDRO 6 (1H TETRAZOL 5 YL) 3 ISOQUINOLINECARBOXYLIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; ISOMERISM; MOUSE; NEUROTRANSMISSION; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR BINDING; RIGIDITY; STRUCTURE ACTIVITY RELATION;

ANIMAL; BINDING, COMPETITIVE; EXCITATORY AMINO ACID ANTAGONISTS; ISOQUINOLINES; MICE; MOLECULAR STRUCTURE; PIGEONS; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE; TETRAZOLES;

EID: 0028865828     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00025a005     Document Type: Article

References (32)

1. Cunningham, M. D.; Ferkany, J. W.; Enna, S. J. Excitatory amino acid receptors: a gallery of new targets for pharmacological intervention. Life Sci. 1993, 54, 135-148.
2. Scatton, B. Excitatory amino acid receptor antagonists: a novel treatment for ischemic cerebrovascular diseases. Life Sci. 1994, 55, 2115-2124.
3. Wrathall, J. R.; Choinere, D.; Teng, Y. D. Dose-dependent reduction of tissue loss and functional impairment after spinal cord trauma with the AMPA/kainate antagonist NBQX. J. Neurosci. 1994, 14, 6598-6607.
4. Bullcok, R.; Fujisawa, H. The role of glutamate antagonists for the treatment of CNS injury. J. Neurotraum. 1992, 9 (Suppl. 2), S443-S462.
5. Greenamyre, J. T.; Maragos, W. F. Neurotransmitter receptors in Alzheimer disease. Cerebrovasc. Brain Metab. Rev. 1993, 5, 61-94.
6. Meldrum, B. S. the role of glutamate in epilepsy and other CNS disorders. Neurology 1994, 44 (Suppl. 8), S14-S23.
7. McQuaid, L. A.; Smith, E. C. R.; South, K. K.; Mitch, C. H.; Schoepp, D. D.; True, R. A.; Calligaro, D. O.; O’Malley, P. J.; Lodge, D.; Omstein, P. L. Synthesis and excitatory amino acid pharmacology of a series of heterocyclic fused quinoxalinones and quinazolinones. J. Med. Chem. 1992, 35, 3319-3324.
8. Carling, R. W.; Leeson, P. D.; Moore, K. W.; Smith, J. D.; Moyes, C. R.; Mawer, I. M.; Thomas, S.; Chan, T.; Baker, R.; Foster, A. C.; Grimwood, S.; Kemp, J. A.; Marshall, G. R.; Tricklebank, M. D.; Saywell, K. L. 3-Nitro-3, 4-dehydro-2 (l. ff)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and CRS)-a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J. Med. Chem. 1993, 36, 3397-3408.
9. Cordi, A.; Desos, P.; Laepagnol, J.; Randle, J. 3-Sulfonylamino-2-(1H)-quinoleinone et des derives 7-aza comme angatonistes d’acides amines excitateurs. (Preparation of 7-aza-3-sulfony-lamino-2-(1H)-quinolinones as excitatory amino acid antagonists.) European Patent Application, 1993, 0 542 609 Al.
10. Ornstein, P. L.; Schoepp, D. D.; Arnold, M. B.; Augenstein, N. K.; Lodge, D.; Millar, J. D.; Chambers, J. W.; Campbell, J.; Paschal, J. W.; Zimmerman, D. M. and Leander, J. D. 6-Substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists. J. Med. Chem. 1992, 35, 3547-3560.
11. Ornstein, P. L.; Arnold, M. B.; Augenstein, N. K.; Deeter, J. B.; Leander, J. D.; Lodge, D.; Calligaro, D. O.; Schoepp, D. D. Unusual stereochemical preferences of decahydroisoquinoline-3-carboxylic acid competitive NMDA antagonists. BioMed. Chem. Lett. 1993, 3, 2067-2072.
12. Ornstein, P. L.; Arnold, M. B.; Augenstein, N. K.; Lodge, D.; Leander, J. D.; Schoepp, D. D. 3SR, 4aRS, 6RS, 8aRS-6-(2-(1H-Tetrazol-5-yl) ethyl) decahydroisoquinoline-3-carboxylic acid: A structurally novel, systemically active, competitive AMPA receptor antagonist. J. Med. Chem. 1993, 36, 2046-2048.
13. Ornstein, P. L.; Augenstein, N. K.; Arnold, M. B. Stereoselective synthesis of 6-substituted decahyroisoquinoline-3-carboxylates: Intermediates for the preparation of conformationally constrained acidic amino acids. J. Org. Chem. 1994, 59, 7862-7869.
14. 3H]-CGS-19755: a novel N-methyl-D-aspartate antagonist with nanomolar affinity in rat brain. Br. J. Pharmacol. 1988, 95, 932-938.
15. Nielsen, E. O.; Madsen, U.; Schaumburg, K.; Krogsgaard-Larsen, P. Studies on receptor-active conformations of excitatory amino acid agonists and antagonists. Eur. J. Med. Chem. Chim. Ther. 1986, 21, 433-437.
16. 3H]kainic acid, an analogue of L-glutamate. J. Neurochem. 1976, 26, 141-147.
17. Harrison, N. L.; Simmonds, M. A. Quantitative studies on some antagonists of iV-methyl-D-aspartate in slices of rat cerebral cortex. Br. J. Pharmacol. 1985, 84, 381-391.
18. Leander, J. D.; Lawson, R. R.; Ornstein, P. L.; Zimmerman, D. M. N-methyl-D-aspartic acid-induced lethality in mice: selective antagonism by phencyclidine-like drugs. Brain Res. 1988, 448, 115-120.
19. Leander, J. D.; Rathbun, R. C.; Zimmerman, D. M. Anticonvulsant effects of phencyclidine-like drugs: Relation to N-methyl-D-aspartic acid antagonism. Brain Res. 1988, 454, 368-372.
20. Turski, L.; Jacobsen, P.; Honore, T.; Stephens, D. N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the a/p) ia-amino-3-hydroxy-5-methyl-4-isoxazoleprorpionate antagonist 2, 3-dihydroxy-6-nitro-7-sulfamoyl-benzo (f) quinoxaline. J. Pharmacol. Exp. Ther. 1992, 260, 742-747.
21. Schoepp, D. D.; Ornstein, P. L.; Leander, J. D.; Lodge, D.; Salhoff C. R.; Zimmerman, D. M. Pharmacological characterization of LY233053: A sturctually novel tetrazole substituted competitive NMDA antagonist with a short duration of action. J. Pharmacol. Exp. Ther. 1990, 255, 1301-1308.
22. Schoepp, D. D.; Lodge, D.; Bleakman, D.; Leander, J. D.; Tizzano, J. P.; Wright, R. A.; Palmer, A. J.; Salhoff, C. R.; Ornstein, P. L. In vitro and in vivo antagonism of AMPA receptor activation by 3S, 4aR, 6R, 8aR-6-(2-(1ff-tetrazol-5-yl) ethyl) decahydroisoquinoline-3-carboxylic acid. Neuropharmacology 1995, in press.
23. Tamawa, I.; Farkas, S.; Berzsenyi, P.; Pataki, A.; Andrasi, F. Electrophysiological studies with a 2, 3-benzodiazepine muscle relaxant: GYKI 52466. Eur. J. Pharmacol. 1989, 167, 193-199.
24. Kaku, D. A.; Goldberg, M. P.; Choi, D. W. Antagonism of non-NMDA receptors augments the neuroprotective effect of NMDA receptor blockade in cortical cultures subjected to prolonged deprivaiton of oxygen and glucose. Brain Res. 1991, 554, 344-347.
25. Loscher, W.; Honack, D. Over-additive anticonvulsant effect of memantine and NBQX in kindled rats. Eur. J. Pharmacol. 1994, 259, R3-R5.
26. Xue, D.; Huang, Z.-G.; Barnes, K.; Lesiuk, H. J.; Smith, K. E.; Buchan, A. M. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J. Cereb. Blood Flow Metab. 1994, 14, 251-261.
27. Buchan, A. M.; Lesiuk, H.; Barnes, K. A.; Li, H.; Huang, A.-G.; Smith, K. E.; Xue, D. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists. Stroke [Suppl. 1] 1993, 24, 1148-1152.
28. Olney, J. W.; Labruyere, J.; Price, M. T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989, 244, 1360-1362.
29. Fix, A. S.; Horn, J. W.; Truex, L. L.; Smith, R. A.; Gomez, E. Neuronal vacuole formation in the rat posterior cingulate/ retrosplinial cortex after treatment with the N-methyl-D-aspartate (NMDA) antaognist MK-801 (dizocilpine maleate). Acta Neuropathol. 1994, 88, 511-519.
30. Hargreaves, R. J.; Rigby, M.; Smith, D.; Hill, R. G.; Iversen, L. L. Competitive as well as uncompetitive IV-methyl-D-aspartate antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem. Res. 1993, 18, 1263-1269.
31. Hargreaves, R. J.; Hill, R. G.; Iversen, L. L. Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. Acta Neurochir. 1994, 60 (Suppl.), 15-19.
32. Browne, S. E.; McCulloch, J. AMPA receptor antagonists and local cerebral glucose utilization in the cat. Brain Res. 1994, 641, 10-20.